ISCT 2026

Scientific Annual Meeting

May 6–9 | Dublin, Ireland

Logo

ISCT 2026

Scientific Annual Meeting

A trusted partner for the next era of cell therapy manufacturing

Experience the future of cell and gene therapy at the ISCT 2026 Scientific Annual Meeting in Dublin. Miltenyi Biotec is shaping the path from early innovation to commercial reality with integrated solutions and services designed to support robust, scalable, and compliant manufacturing strategies. As the field advances toward broader patient access, key questions around centralized versus decentralized and point-of-care manufacturing are coming into focus.

Through collaboration and deep expertise across science, technology, and regulation, we enable informed decisions that drive consistency, efficiency, and sustainable scale.

Join us at booth #1107 to explore how manufacturing models, partnerships, and a shared vision will define the future of cell therapy delivery.

The Convention Centre Dublin Spencer Dock Dublin, Ireland

Miltenyi Biotec booth #1107

May 6–8, 2026 | Exhibit opening hours

Wednesday, May 6 | 11:30 a.m.–08:00 p.m.

Thursday, May 7 | 9:00 a.m.–6:00 p.m.

Friday, May 8 | 8:00 a.m.–4:00 p.m.

What are you interested in?

Content

  • Corporate program
  • Poster presentations
  • Solutions
Artboard Copy

Corporate program

Corporate session

Shaping the future of cell therapy: manufacturing models to expand patient access and enable commercial scale

As cell therapies move toward wider clinical use, the choice between centralized and point‑of‑care manufacturing has become a key strategic question. This session brings together experts from biotech, biopharma, and clinical centers to examine how these models shape the path from early development to commercial readiness and influence the reliable delivery of therapies to patients.

Through talks and a multi‑stakeholder panel, we will explore the scientific, regulatory, and operational factors behind manufacturing decisions, including process scaling, product consistency, and evolving regulatory expectations. The session will highlight where clinical and industry perspectives align, or diverge, and how collaboration can help overcome current barriers.

Together, we will reassess the future landscape of cell therapy manufacturing and the strategies needed to move from innovation to sustainable, large‑scale delivery.

Wednesday, May 6 | 3:45–5:15 p.m.

*Exact time subject to change.

Wicklow Hall 2

Speakers

Portrait image
Chair

Cristina Conforti Andreoni, PhD

Miltenyi Biotec, Germany

Chair information

Cristina Conforti Andreoni obtained her PhD in translational medicine at the University of Milan-Bicocca, Italy, in collaboration with SIgN, A-STAR Singapore, researching the dendritic cell response to danger signals. After a post-doctoral fellowship on the same project and her role as Scientific Officer at the biotech startup Ayoxxa at the National University of Singapore, she joined Miltenyi Biotec in Bergisch Gladbach, Germany as Global Product Manager for Cell Culture.

In 2018, she took over the Group Leader position of the Translational Immunology Team with a focus on myeloid cells, B cells, and NK cells. Since 2023, she is the Portfolio Strategy Manager for Immunotherapy, with a special focus on the network of the academic development of cell and gene therapies, and recently was appointed an overviewing role on the clinical trial supply of the supported clinical trials.

Speaker portrait Navarro

Barcelona's point‑of‑care CAR T model expands national patient access

Sergio Navarro Velázquez, MS

Hospital Clínic de Barcelona, Spain

Abstract

The Hospital Clínic de Barcelona, together with Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), has built a point‑of‑care CAR T cell model that brings locally manufactured academic therapies (ARI‑0001 for relapsed/refractory ALL and ARI‑0002h for multiple myeloma) directly into Spain’s public healthcare system. By producing non‑industrial Advanced Therapy Medicinal Products (ATMPs) onsite rather than relying on centralized commercial facilities, the model reduces costs, shortens logistics, and removes traditional manufacturing bottlenecks.

This decentralized approach enables hospitals across Spain to refer and treat patients within a coordinated national network. Since 2017, more than 500 patients have received therapy through this framework, demonstrating that hospital‑based manufacturing can meaningfully increase accessibility, affordability, and scalability of CAR T therapies within a national health system.

Speaker information

Sergio Navarro Velázquez is a Specialist in Immunology at the Hospital Clínic de Barcelona, where he has worked since 2022 in the Immunotherapy Section of the Immunology Department. He brings prior experience as a Clinical Research Associate and as a specialist in training, with a strong foundation in immunology, immunotherapy, bioinformatics, and biostatistics. His background reflects a solid clinical–scientific profile aligned with advancing next‑generation immunotherapies within leading academic healthcare environments.

Natasha Kekre, MD, Ottawa Hospital Research Institute, Canada
Academic PoC CAR T in Canada: opportunities and challenges getting to market

Natasha Kekre, MD

Ottawa Hospital Research Institute, Canada

Abstract

Dr. Kekre will delve into the many unique challenges faced in the journey to offer CAR T cell therapy to patients across Canada, particularly those who may have otherwise run out of treatment options. Since its inception in 2016, the Canadian Led Immunotherapies Collaborative (CLIC) program has been at the forefront of this innovative treatment approach. By bringing together researchers, clinicians, and patients from across Canada, CLIC has focused on building expertise and expanding capacity for innovation in the rapidly evolving field of cellular immunotherapy.

The program's first clinical trial was launched in 2019, starting with two sites in Canada, but it has since grown into a robust network encompassing multiple clinical and manufacturing sites across the country. In this presentation, Dr. Kekre will highlight the story behind the building of research capacity within CLIC, shedding light on the numerous trials and tribulations faced during the process of bringing a cell therapy product, manufactured on the CliniMACS Prodigy®, to market authorization and standard of care in Canada.

Speaker information

Dr. Natasha Kekre is a hematologist at The Ottawa Hospital and a scientist at the Ottawa Hospital Research Institute, where she also serves as an associate professor of medicine at the University of Ottawa. With training in hematology, stem‑cell transplantation (Dana‑Farber Cancer Institute), and public health (Harvard University), she leads early‑phase clinical trials and translational programs focused on advancing Canadian‑developed cell therapies. Her work drives national efforts to establish a Canadian CAR T platform, strengthening access to innovative therapies for patients across the country.

Kostadinka Lilova, PhD, Executive Director, Cell Process Development, Product Delivery, Autolus Therapeutics, UK
More than a year on: a review of commercial manufacturing from process development perspectives

Koki Lilova, PhD

Autolus Therapeutics, UK

Abstract

Koki Lilova, PhD, reflects on the process development point of view more than a year after the successful launch of Aucatzyl, with a few hundred patient batches manufactured with single-digit out-of-specification (OOS) results and a very low rate of manufacturing failures. Exploring how continuous process understanding impacts further control strategy iteration, she also draws on lessons learned from the commercial analytical experience, highlighting where analytical methods still have room for improvement, including transduction efficiency and functionality testing. In addition, she discusses actions that could have been performed prior to regulatory filings to avoid some of the OOS and manufacturing failures.

Speaker information

Kostadinka Lilova, PhD, is Executive Director for Cell Process Development at Autolus Therapeutics. Her education was completed across two different parts of the world, Bulgaria and Canada, where she earned degrees in chemical and biochemical engineering, respectively. She has worked in cell therapy process development since 2007. For the past six years, her focus has been on immuno-oncology process development for NK allogeneic and T cell autologous products, first at Janssen Pharmaceuticals and, since 2021, at Autolus Therapeutics.

Poster presentations

Process development and manufacturing

Wednesday, May 6

7:00–8:30 p.m.

#928

Development of a closed-system workflow for end-to-end processing of human pluripotent stem cells from reprogramming to expansion

Frank Jüngerkes

Team Coordinator, R&D Miltenyi Biotec, Germany

#947

Increasing filling precision: advances in the CliniMACS Prodigy® TCTf process

Marcel Maluski

Associate Director, R&D Miltenyi Biotec, Germany

#951

Next-generation automated clinical-grade CAR NK cell manufacturing
using advanced cell separation technology

Angela Mekes

Team Coordinator, R&D Miltenyi Biotec, Germany

iPSC

Wednesday, May 6

12:00–01:00 p.m.

Elevator pitch competition

#1511

Label-free isolation of iPSC-derived retinal pigmented epithelial cells

Daryl Grummit

Senior Scientific Consultant, Miltenyi Biotec Inc., USA

#1188

Deconvolution of CAR T cell in vivo trafficking and infiltration in PDAC

Valeriia Lebedeva

PhD student, R&D Miltenyi Biotec, Germany

#708

Analytical performance of IFN-γ quantification for T cell functional
characterization using a cytokine bead assay

Cesar Evaristo

Group Leader, R&D Miltenyi Biotec, Germany

Thursday, May 7

6:00–7:30 p.m.

#1511

Label-free isolation of iPSC-derived retinal
pigmented epithelial cells

Daryl Grummit

Senior Scientific Consultant, Miltenyi Biotec Inc., USA

#1520

A new culture medium for three-dimensional
expansion of human pluripotent stem cells

Frank Jüngerkes

Team Coordinator, R&D Miltenyi Biotec, Germany

Immunotherapy

Thursday, May 7

6:00–7:30 p.m.

#1123

Manipulation of T cell program in CAR T cell therapy

Aleksandra Bugakova

PhD student, R&D Miltenyi Biotec, Germany

#1145

Precise and flexible formulation and filling in an automated end-to-end CAR T cell manufacturing system – the CliniMACS Prodigy® TCTf process

Britta Drees

Team Coordinator, R&D Miltenyi Biotec, Germany

#1188

Deconvolution of CAR T cell in vivo trafficking and infiltration in PDAC

Valeriia Lebedeva

PhD student, R&D Miltenyi Biotec, Germany

#1193

Dried antibody cocktails are setting the benchmark for fast and robust CAR T cell flow cytometric analysis

Lovlesh Lovlesh

Junior Product Manager, Miltenyi Biotec, Germany

Regulatory affairs and quality systems

Thursday, May 7

6:00–7:30 p.m.

#708

Analytical performance of IFN-γ quantification for T cell functional
characterization using a cytokine bead assay

Cesar Evaristo

Group Leader, R&D Miltenyi Biotec, Germany

Solutions

Abstract illustration of a high-speed boat racing toward a bright horizon along glowing blue pathways
Power behind CGT

Commercially proven.
Scalable by design.
Trusted worldwide.

See what drives commercial CGT forward and how Miltenyi Biotec supports every step from concept to market readiness.

Two employees wearing clean room attire sharing data.

Experience Miltenyi Bioindustry

CDMO services to actualize your cell and gene therapy program

Learn more

Contact us

Interested in connecting? Get in touch to schedule a time, either during ISCT or later, in person or virtually.

Miguel Lopez, Global Product Manager CliniMACS Instruments

You have previously chosen International as your location.
What do you want to do?